Aerovate Therapeutics Inc
AVTE2.680USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
77.68MMarket Cap
LossP/E TTM
More Details of Aerovate Therapeutics Inc Company
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.
Aerovate Therapeutics Inc Info
Ticker SymbolAVTE
Company nameAerovate Therapeutics Inc
IPO date- -
CEOMr. Timothy P. Noyes
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address930 Winter Street
CityWALTHAM
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02451
Phone16174432400
Websitehttps://www.aerovatetx.com/
Ticker SymbolAVTE
IPO date- -
CEOMr. Timothy P. Noyes
Company Executives of Aerovate Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Benjamin T. Dake, Ph.D.
Dr. Benjamin T. Dake, Ph.D.
President, Chief Operating Officer, Secretary
President, Chief Operating Officer, Secretary
505.00
+9.31%
Mr. Bradford D. (Brad) Dahms
Mr. Bradford D. (Brad) Dahms
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Marinus Verwijs, Ph.D.
Dr. Marinus Verwijs, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Ralph Niven, Ph.D.
Dr. Ralph Niven, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Director
Independent Director
--
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Joshua Resnick, M.D.
Dr. Joshua Resnick, M.D.
Independent Director
Independent Director
--
--
Mrs. Susan Fischer
Mrs. Susan Fischer
Executive Vice President - Development Operations
Executive Vice President - Development Operations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Benjamin T. Dake, Ph.D.
Dr. Benjamin T. Dake, Ph.D.
President, Chief Operating Officer, Secretary
President, Chief Operating Officer, Secretary
505.00
+9.31%
Mr. Bradford D. (Brad) Dahms
Mr. Bradford D. (Brad) Dahms
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Marinus Verwijs, Ph.D.
Dr. Marinus Verwijs, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Ralph Niven, Ph.D.
Dr. Ralph Niven, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.41%
Fairmount Funds Management LLC
9.90%
VR Adviser, LLC
7.00%
RA Capital Management, LP
6.99%
Janus Henderson Investors
6.66%
Other
59.04%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.41%
Fairmount Funds Management LLC
9.90%
VR Adviser, LLC
7.00%
RA Capital Management, LP
6.99%
Janus Henderson Investors
6.66%
Other
59.04%
Shareholder Types
Shareholders
Proportion
Hedge Fund
22.92%
Venture Capital
20.14%
Investment Advisor
19.67%
Investment Advisor/Hedge Fund
16.64%
Private Equity
4.23%
Individual Investor
0.95%
Research Firm
0.50%
Bank and Trust
0.08%
Pension Fund
0.02%
Other
14.85%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
217
31.51M
96.73%
+18.51M
2025Q2
214
13.42M
41.64%
+12.20M
2025Q1
214
927.53K
47.43%
-347.78K
2024Q4
217
30.84M
106.81%
-7.10M
2024Q3
214
28.32M
98.10%
-8.69M
2024Q2
210
27.84M
96.65%
-3.71M
2024Q1
181
29.16M
104.58%
-1.74M
2023Q4
173
28.88M
104.29%
-1.94M
2023Q3
168
28.55M
103.17%
-3.10M
2023Q2
169
28.55M
103.46%
+487.13K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
4.74M
14.52%
+232.00
+0.00%
Jun 30, 2025
Fairmount Funds Management LLC
3.22M
9.87%
--
--
Jun 30, 2025
VR Adviser, LLC
3.22M
9.87%
+3.13M
+3399.98%
Jun 30, 2025
RA Capital Management, LP
1.06M
3.26%
-262.63K
-19.82%
Jun 30, 2025
Deep Track Capital LP
2.51M
7.69%
+2.43M
+3053.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.56M
4.78%
+1.54M
+6191.66%
Jun 30, 2025
The Vanguard Group, Inc.
1.81M
5.54%
+1.78M
+5829.22%
Jun 30, 2025
Versant Ventures
1.53M
4.68%
+1.53M
--
Jun 30, 2025
RTW Investments L.P.
1.45M
4.44%
+1.45M
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Value ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
ProShares Hedge Replication ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
ALPS Medical Breakthroughs ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.06%
iShares Russell 2000 Value ETF
Proportion0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
ALPS Medical Breakthroughs ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Aerovate Therapeutics Inc?
The top five shareholders of Aerovate Therapeutics Inc are:
Fidelity Management & Research Company LLC holds 4.74M shares, accounting for 14.52% of the total shares.
Fairmount Funds Management LLC holds 3.22M shares, accounting for 9.87% of the total shares.
VR Adviser, LLC holds 3.22M shares, accounting for 9.87% of the total shares.
RA Capital Management, LP holds 1.06M shares, accounting for 3.26% of the total shares.
Deep Track Capital LP holds 2.51M shares, accounting for 7.69% of the total shares.
Fidelity Management & Research Company LLC holds 4.74M shares, accounting for 14.52% of the total shares.
Fairmount Funds Management LLC holds 3.22M shares, accounting for 9.87% of the total shares.
VR Adviser, LLC holds 3.22M shares, accounting for 9.87% of the total shares.
RA Capital Management, LP holds 1.06M shares, accounting for 3.26% of the total shares.
Deep Track Capital LP holds 2.51M shares, accounting for 7.69% of the total shares.
What are the top three shareholder types of Aerovate Therapeutics Inc?
The top three shareholder types of Aerovate Therapeutics Inc are:
Fidelity Management & Research Company LLC
Fairmount Funds Management LLC
VR Adviser, LLC
Fidelity Management & Research Company LLC
Fairmount Funds Management LLC
VR Adviser, LLC
How many institutions hold shares of Aerovate Therapeutics Inc (AVTE)?
As of 2025Q3, 217 institutions hold shares of Aerovate Therapeutics Inc, with a combined market value of approximately 31.51M, accounting for 96.73% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 55.09%.
What is the biggest source of revenue for Aerovate Therapeutics Inc?
In --, the -- business generated the highest revenue for Aerovate Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
